CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
健康社会决定因素对复发/难治性 B 细胞急性淋巴细胞白血病成人患者 brexucabtagene autoleucel 治疗结局的影响
英文原题：The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
查看英文原题
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Brexucabtagene autoleucel（brexu-cel）是一种CAR-T（CAR-T）细胞疗法，获批用于复发/难治性（R/R）B细胞急性淋巴细胞白血病（B-ALL）成人患者。
我们研究了健康社会决定因素（SDoH）对接受brexu-cel治疗的B-ALL成人患者结局的影响。这项回顾性分析纳入2021年至2023年间接受brexu-cel治疗的R/R B-ALL成人患者（18岁）。采用Cox比例风险模型评估种族、族裔和SDoH与无进展生存期（PFS）和总生存期（OS）的相关性。189例患者接受了brexu-cel，57%为男性。55%为非西班牙裔白人，30%为西班牙裔，7%为非西班牙裔黑人，6%为亚裔/太平洋岛民，2%为其他/未知。43%由私立/社区诊所转诊，35%居住在距CAR-T 中心50英里或以上。医疗保险包括公共保险（47%）和私人保险（41%）。31%具有高社会剥夺指数（SDI，第76-99百分位）。黑人种族与较差的OS相关（HR 3.48；95% CI 1.01-12.03）。西班牙裔患者的PFS（HR 1.03，95% CI 0.50-2.10）或OS（HR 1.43；95% CI 0.56-3.65）无差异。结局似乎独立于SDoH，且SDoH未影响OS。我们观察到与非西班牙裔患者相当的结局。
展开英文摘要原文
Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T (CAR T) cell therapy approved for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
We studied the impact of social determinants of health (SDoH) on outcomes of adults with B-ALL receiving brexu-cel. This retrospective analysis included adults ( 18 years) with R/R B-ALL treated with brexu-cel between 2021 and 2023. Cox proportional hazards models evaluated the association of race, ethnicity, and SDoH with progression-free survival (PFS) and overall survival (OS). 189 patients received brexu-cel and 57% were male. 55% were non-Hispanic White, 30% Hispanic, 7% non-Hispanic Black, 6% Asian/Pacific Islander, and 2% other/unknown.
43% were referred from private/community-based practices and 35% lived 50 miles or greater from the CAR T center. Health insurance included public (47%) and private (41%). 31% had a high social deprivation index (SDI, 76-99th percentile). Black race was associated with worse OS (HR 3. 48; 95% CI 1. 01-12. 03). There was no difference in PFS (HR 1. 03, 95% CI 0. 50-2. 10) or OS (HR 1. 43; 95% CI 0. 56-3. 65) in Hispanic patients. Outcomes appear independent of SDoH and SDoH did not impact OS.
We observed comparable outcomes to non-Hispanic patients.
论文信息
- 作者
- O'Connor TE、Lin C、Roloff GW、Zhang A、Miller K、Aldoss I、Kopmar NE、Dekker SE
- 第一作者单位
- Loyola University Medical Center, Maywood, IL, USA.United States
- 通讯作者单位
- Vanderbilt University Medical Center, Nashville, TN, USA. Bhagirathbhai.R.Dholaria@vumc.org.United States
- 期刊
- Bone marrow transplantation2025 Nov
- 原文标识
- PubMed 40849364 · DOI 10.1038/s41409-025-02693-0
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →